- Trials with a EudraCT protocol (1,319)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,319 result(s) found for: Small cell lung cancer.
Displaying page 7 of 66.
| EudraCT Number: 2020-005602-26 | Sponsor Protocol Number: FL-101-2001 | Start Date*: 2021-08-03 | ||||||||||||||||||||||||||
| Sponsor Name:Flame Biosciences | ||||||||||||||||||||||||||||
| Full Title: A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer | ||||||||||||||||||||||||||||
| Medical condition: Surgically resectable non-small cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2008-001736-12 | Sponsor Protocol Number: NO21160 | Start Date*: 2008-11-12 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients wit... | ||||||||||||||||||
| Medical condition: To investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have f... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) ES (Completed) AT (Prematurely Ended) DE (Completed) IE (Completed) IT (Completed) FR (Completed) GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-000738-36 | Sponsor Protocol Number: 20120265 | Start Date*: 2013-10-15 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer | |||||||||||||
| Medical condition: Advanced Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) GR (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005541-21 | Sponsor Protocol Number: CBKM120D2204 | Start Date*: 2013-06-20 | |||||||||||||||||||||||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||||||||||||||||||||||
| Full Title: A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-s... | |||||||||||||||||||||||||||||||||
| Medical condition: squamous non small cell lung cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: IT (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-000058-89 | Sponsor Protocol Number: D516AC00001 | Start Date*: 2021-01-06 | |||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
| Full Title: A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treat... | |||||||||||||||||||||||
| Medical condition: Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Ongoing) AT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2012-003544-68 | Sponsor Protocol Number: IRST162.05 | Start Date*: 2012-10-02 | ||||||||||||||||
| Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | ||||||||||||||||||
| Full Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study. | ||||||||||||||||||
| Medical condition: Patients affected by stage IIIB or stage IV NSCLC candidates to receive a first line chemotherapy with vinorelbine due to age ≥ 70 and Eastern Cooperative Oncology Group (ECOG) Performance status ≤... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-016806-18 | Sponsor Protocol Number: TAX-ERB2 | Start Date*: 2010-12-09 | |||||||||||
| Sponsor Name:Klinik Löwenstein gGmbH | |||||||||||||
| Full Title: Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin... | |||||||||||||
| Medical condition: patients with advanced or metastatic NSCLC | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-003201-96 | Sponsor Protocol Number: I4X-MC-JFCK | Start Date*: 2013-03-13 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Ce... | |||||||||||||
| Medical condition: Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001726-13 | Sponsor Protocol Number: A4061038 | Start Date*: 2008-11-28 | ||||||||||||||||||||||||||
| Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York City, NY 10017 | ||||||||||||||||||||||||||||
| Full Title: PHASE 2 TRIAL OF AG-013736 AS FIRST-LINE TREATMENT FOR PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER RECEIVING TREATMENT WITH CISPLATIN AND GEMCITABINE | ||||||||||||||||||||||||||||
| Medical condition: Advanced non-small cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: PL (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2008-006384-37 | Sponsor Protocol Number: NP22383 | Start Date*: 2009-10-06 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
| Full Title: A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC). | |||||||||||||||||||||||
| Medical condition: Patients with recurrent or refractory stage IIIB/IV NSCLC. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2018-001994-25 | Sponsor Protocol Number: TACTI-002(IMP321P015);KeynotePN798 | Start Date*: 2019-02-12 | ||||||||||||||||||||||||||
| Sponsor Name:Immutep S.A.S. | ||||||||||||||||||||||||||||
| Full Title: TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurren... | ||||||||||||||||||||||||||||
| Medical condition: Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or recurrent or metastatic squamous head and neck cancer (HNSCC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-000556-35 | Sponsor Protocol Number: D910LC00001 | Start Date*: 2020-12-01 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ... | |||||||||||||
| Medical condition: Completely Resected Stage II-III NSCLC | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005546-36 | Sponsor Protocol Number: P051084 | Start Date*: 2007-05-11 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Effet d'une héparine de bas poids moléculaire sur la mortalité du cancer bronchique non à petites cellules de stade I, II ou IIIa. Un essai multicentrique, randomisé, ouvert. | |||||||||||||
| Medical condition: cancer bronchique non à petites cellules de stade I, II ou IIIa | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-002224-40 | Sponsor Protocol Number: OAM4971g | Start Date*: 2012-05-14 | |||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | |||||||||||||||||||||||
| Full Title: A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with Tarceva® (erlotinib) in Patients with Me... | |||||||||||||||||||||||
| Medical condition: MET DIAGNOSTIC−POSITIVE NON−SMALL CELL LUNG CANCER (NSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) ES (Completed) DE (Completed) HU (Completed) IE (Completed) NL (Completed) GB (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-003953-13 | Sponsor Protocol Number: PPHM1202 | Start Date*: 2014-04-01 | ||||||||||||||||
| Sponsor Name:Peregrine Pharmaceuticals, Inc. | ||||||||||||||||||
| Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non... | ||||||||||||||||||
| Medical condition: Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) BE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) GR (Prematurely Ended) RO (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2005-006022-29 | Sponsor Protocol Number: A6181058 | Start Date*: 2006-05-26 | |||||||||||
| Sponsor Name:PFIZER | |||||||||||||
| Full Title: RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF ERLOTINIB WITH OR WITHOUT SU011248 IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER | |||||||||||||
| Medical condition: Platinum-refractory, locally advanced or metastatic non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) HU (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002372-89 | Sponsor Protocol Number: CA001-030 | Start Date*: 2016-04-29 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer | |||||||||||||
| Medical condition: Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006780-37 | Sponsor Protocol Number: BT-CL-PGG-LCA0821 | Start Date*: 2009-03-06 | |||||||||||||||||||||
| Sponsor Name:Biothera | |||||||||||||||||||||||
| Full Title: A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated A... | |||||||||||||||||||||||
| Medical condition: Patients with with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2008-002072-10 | Sponsor Protocol Number: 1199.14 | Start Date*: 2009-02-27 | |||||||||||||||||||||
| Sponsor Name:Boehringer Ingelheim International GmbH | |||||||||||||||||||||||
| Full Title: Multicenter, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy... | |||||||||||||||||||||||
| Medical condition: Stage IIIB/IV or recurrent non small cell lung cancer. non squamous histology | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) RO (Temporarily Halted) PL (Completed) DE (Completed) BG (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-003075-39 | Sponsor Protocol Number: TXTGEM OVER 70 | Start Date*: 2007-07-12 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
| Full Title: PROTOCOL OF TREATMENT WITH DOCETAXEL-GEMCITABINE IN OLD OR UNFIT PATIENTS WITH NSCLC STAGE IIIA, IIIB E IV. PHASE II TRIAL | |||||||||||||
| Medical condition: Enrolment of old or unfit patient with age over 70, with Non Small Cell Lung Cancer, not operable stage IIIA, IIIB, IV | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
